Lupin Ltd — Board/Management Information 2019

Oct 3, 2019

REUTERS: LUPIN.BO

BLOOMBERG: LPCIN

==> picture [169 x 32] intentionally omitted <==

----- Start of picture text ----- Press Release----- End of picture text -----

==> picture [45 x 53] intentionally omitted <==

BSE: 500257 NSE: LUPIN

Lupin appoints Sreeji Gopinathan as Chief Information Officer

Mumbai, October 03, 2019 : Pharma major Lupin Limited announced today the appointment of Sreeji Gopinathan as Chief Information Officer (CIO). He will lead the IT function for Lupin globally, based in Mumbai.

Sreeji brings to Lupin over 20 years of significant domain expertise and global experience. Most recently, Sreeji was with Reckitt Benckiser. Prior to that, he was associated with Philips, Procter & Gamble, ISRO and Asea Brown Boveri. Sreeji holds a Master’s degree in Business Administration from the University of Edinburgh, UK and B. Tech (Applied Electronics and Instrumentation) from the University of Kerala.

Commenting on the appointment, Nilesh Gupta - Managing Director, Lupin said, “We have built a very solid Information Technology foundation, whether it pertains to our manufacturing operations, our sales operations or our HR processes. With Sreeji’s joining, Lupin’s IT function will be further strengthened. With his substantial experience and ability to closely work with businesses, he will expand and invigorate our initiatives in digitization, process automation, data management and analytics which will eventually help improve business results.”

About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 8[th] largest generics pharmaceutical company by revenues (31[st] Mar 2019, Bloomberg LTM) respectively. The Company is the 3[rd] largest pharmaceutical player in the US by prescriptions (IQVIA MAT Jun 2019); 3[rd] largest Indian pharmaceutical company by global revenues (31[st] Mar 2019, Bloomberg LTM); 5[th] largest generic pharmaceutical player in Japan and 6[th] largest company in the Indian Pharmaceutical Market (IQVIA MAT Jun 2019).

For the financial year ended 31[st] March, 2019, Lupin’s Consolidated sales and Net profits were at Rs. 163,694 million (USD 2.34 billion) and Rs. 9,466 million (USD 136 million) respectively. Please visit http://www.lupin.com for more information. You could also follow us on Twitter – www.twitter.com/lupinglobal

CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.

For further information or queries please contact – Arvind Bothra Head – Investor Relations and M&A / Corporate Communications Email: arvindbothra@lupin.com Ph: +91-22-66408237